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Abstract
The aim of this study was to determine the basis for anti-tumor immune reactivity observed in
patients with human epidermal growth factor receptor-2 (HER-2) (3+) breast carcinoma using an
in vitro model in which the role of the HER-2-specific monoclonal antibody Herceptin was also
investigated. Patients with metastatic breast cancer who had their primary tumor resected were
included in this study. Peripheral blood mononuclear cell (PBMC)-dependent cytotoxicity in the
presence or absence of Herceptin were assessed using the survival of target breast
adenocarcinoma MDA-MB-361 cells as a parameter in a (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) test. We observed a significant increase in PBMC-dependent
cytotoxicity when autologous serum was introduced in the assay. Furthermore, the addition of
Herceptin significantly increases their cytotoxicity. These data suggest that autologous serum
constitutively contains factors that might affect PBMC-dependent cytotoxic activity against HER-2
positive cancer cells.
Introduction
In order to improve the unsatisfying results of current
standard approaches to breast cancer treatment, therapeu-
tic strategies tailored to individual patients' tumor pheno-
type based on better understanding of breast cancer
biology should be considered. For instance, the human
epidermal growth factor receptor-2 (HER-2/ErbB-2) is
over-expressed in 25–30% of breast and ovarian cancers
and has been broadly utilized as a target for passive
immunotherapeutical interventions [1] in particular with
the humanized anti-HER-2 monoclonal antibody trastu-
zumab (Herceptin) [2]. The mechanisms of anti-tumor
activity of Trastuzumab are complex and still not fully
understood. Trastuzumab induces rapid disappearence of
HER-2 from the cell surface, thereby reducing het-
erodimer formation critical for the accumulation of the
cyclin-dependent kinase inhibitor p27 resulting in cell
cycle arrest [3]. It also appears that Trastuzumab sup-
presses VEGF expression, inhibits heregulin-mediated
angiogenesis both in vitro and in vivo, reverses cytokine
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resistance, and restores E-cadherin expression [4]. Trastu-
zumab also inhibits constitutive HER-2 cleavage/shed-
ding by metalloproteases and, consequently, the
generation of phosphorylated p95 [3,5,6]. Since Trastuzu-
mab contains a human immunoglobulin G1 (IgG1) Fc
region, it is possible that the antibody may participate in
complement mediated cytotoxicity (CMC) and/or anti-
body dependent cell-mediated cytotoxicity (ADCC).
However, Trastuzumab cytotoxicity by CMC could not be
documented experimentally [7], possibly because of the
presence of membrane-bound complement regulatory
proteins (mCRP) such as decay accelerating factor (DAF;
CD55), membrane cofactor protein (MCP; CD46), or pro-
tectin (CD59) on the surface of breast carcinoma cells.
However, its cytotoxicity through ADCC has been con-
firmed [5,6,8]. Herceptin-dependent cell-mediated cyto-
toxicity action could depend upon activation of Fcγ RI
(CD64) in monocytes and dendritic cells and/or activa-
tion of Fcγ RIII, (CD16) in monocytes/macrofages and
natural killer cells, which may release cytotoxic granules
such as perforin and granzymes to destroy target tumor
cells.
Suppression of Herceptin cytotoxicity could be mediated
through Fcγ RII (CD32), constitutively expressed on
monocytes, B cells, platelets, dendritic cells, eosinofils,
basophiles and neutrophils. It is observed that Trastuzu-
mab is particularly effective in patients with strong
(immunohistochemistry score, IHC score = +3) overex-
pression of the HER-2 receptor, or medium over-expres-
sion (IHC score +2) [9]. However, passive
immunotherapy of the breast cancer with Herceptin
appears promising; it remains unclear why some patients
with HER-2 positive tumors do not adequately respond to
therapy. Therefore, the aim of this study was to identify in
vitro, immune parameters, in the patients with breast car-
cinoma that may be relevant to anti-tumor immune mod-
ulation, and to estimate in vitro the capability of Herceptin
to enhance anti-tumor activity in patients with breast can-
cer and normal controls.
Patients, material and methods
Fourteen HER-2 positive advanced breast cancer patients
were included in the study. All patients had histologically
proven invasive breast cancer, diagnosed in the metastatic
stage of the disease immediately before the inclusion (1
patient), or earlier in the operable clinical stages (13
patients). As the consequence of previous cytotoxic and/
or endocrine treatment, most of the patients were post-
menopausal at study entry. However, patients had been
without any systemic endocrine or cytotoxic therapy at
least one month before the serum sampling. All patients
had visceral involvement, mostly including the liver
metastases. All patients had HER-2 (3+) positive primary
tumors according to immunohistochemical examination
using DAKO HercepTest on paraffin embedded breast
tumor specimens. At the time of inclusion, they were
screened for randomization into the clinical study of
chemotherapy with or without trastuzumab. Their
characteristics are presented on Table 1.
The study was approved by Institutional Ethics Commit-
tee. All patients signed the written Informed Consent.
Twenty healthy donors, age range: 20–55 years, served as
controls. Peripheral blood mononuclear cells (PBMC)
cytotoxicity and PBMC and Herceptin-dependent cytotox-
icity were assessed indirectly, through determination of
target, HER-2 positive (3+), breast adenocarcinoma MDA-
MB-361 cell survival, by 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) MTT test [10]. Twenty
thousand target MDA-MB-361 cells (T) were mixed with
effectors PBMC (E), at effectors to target (E:T) ratios of 0:1
and 5:1 for 48 h, in RPMI 1640 medium with 10% of con-
trol serum (pool of healthy sera), or these target cells were
incubated in RPMI 1640 medium with 10% autologous
serum and PBMC at E:T ratios: 0:1, 1.25:1, 2.5:1 and 5:1
with or without 21 µg/ml of Herceptin. After 48 h 20 µl of
MTT solution (5 mg / ml phosphate buffered saline) were
added and 4 h later 100 µl of 10% sodium dodecyl sulfate
were added. The absorbance at 570nm of MTT stained
wells were read at 570 nm 24 h latter.
To get the cell survival, the absorbance at 570 nm of MTT
stained target cells (A) incubated :
• in nutrient medium with autologuous serum (Na),
• or in nutrient medium with autologuous serum plus
efector cells (Na+E),
• or in nutrient medium with control serum (Nc),
• or in nutrient medium with control serum plus efector
cells (Nc+E),
was always devided with the absorbance of control cells
(Ac) i.e., target cells incubated in nutrient medium with
control serum (Nc)
S(%) = A/Ac
It was implied that absorbance of corresponding blank AB
was always substracted from A of samples, or from A of
controls. Therefore final equation was:
S (%) = (A (T+Na+E)-A(Na+E)) / (A(T+Nc) -ANc)
Percent of CD16+ cells was determined by direct immun-
ofluorescence assay using the anti-CD16 FITC mono-Journal of Translational Medicine 2005, 3:13 http://www.translational-medicine.com/content/3/1/13
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Table 1: Patients' characteristics
Total No of BC patients 14
Age at study entry range 36–69
(yrs) median 52.5
Menstrual status premenopausal 1
(No. of pts) postmenopausal 13
Previous treatment None 1
(No. of pts) Surgery radical (breast) 13
biopsy only 1
liver metastasectomy 2
Irradiation – postoperative 4
Systemic therapy adjuvant 11
adj./neo-adj. chemoth 9
adj. endocrine therapy 5
for metastatic disease 7
Min. time elapsed from discontinuation of previous treatments (days) 28
DFI (months) range 0–144
median 26
Histology type of primary tumor IDC 8
(No. of pts) ILC 2
IC 4
Histology grade of primary tumor 1 0
(No. of pts) 2 8
32
unknown 4
SR status Negative (ER neg. and PR neg.) 4
(No. of pts) Positive (ER pos. and/or PR pos.) 10
HER-2 status Positive (3+, ICH) 14
(No. of pts)
Clinical stage of BC at study entry Stage IV 14
1st disease relapse 7
2nd disease relapse 5
3rd disease relapse 2Journal of Translational Medicine 2005, 3:13 http://www.translational-medicine.com/content/3/1/13
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clonal antibodies according to manufacturer's
instructions (Becton Dickinson, San Jose, Ca, USA). Data
collection and analysis were done on FacsCalibur™ flow
cytometer (BDIS), using the CellQuest software (BDIS).
Statistical analysis was done using two-tailed Student's t
test with a minima threshold for significance of P < 0.05).
Results
Serum isolated from healthy controls did not alter MDA-
MB-361 cell growth compared with pooled serum. Sera
from patients did not significantly suppressed the growth
of target tumor cells (P = 0,05006) in comparison to their
growth in pooled serum The survival of target cells grown
in nutrient medium with serum of control healthy people
or with serum of patients in the presence of 21 µg/ml of
Herceptin was also not significantly affected (Figure 1).
PBMC from healthy donors manifested a non-significant
trend toward higher cytotoxicity compared to PBMC from
Metastatic involvement Visceral 14
(No. of pts)
liver involvement 11
other organs involvement 8
BC = Breast cancer; DFI = Disease-free interval; IDC = Invasive ductal carcinoma;
ILC = Invasive lobular carcinoma; IC = Invasive carcinoma of unknown histology type;
SR = Steroid receptors; ER = Estrogen receptor; PR = Progesterone receptor;
HER-2 = Human epidermal growth factor receptor type 2.
Table 1: Patients' characteristics (Continued)
The mean values of the survival (S%) of adenocarcinoma  MDA-MB-361 cells, grown for 48 h in nutrient medium with  10% serum from control healthy people, or from breast car- cinoma patients with, or without Herceptin (21 µg/ml) Figure 1
The mean values of the survival (S%) of adenocarcinoma 
MDA-MB-361 cells, grown for 48 h in nutrient medium with 
10% serum from control healthy people, or from breast car-
cinoma patients with, or without Herceptin (21 µg/ml).
n=20  n=20
controls
n=14  n=14
patients
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The mean values of survival (S%) of MDA-MB-361 cells co- cultured for 48 h, with effectors, PBMC isolated from control  healthy people and from breast carcinoma patients, in nutri- ent medium with 10% of control, or autologous serum Figure 2
The mean values of survival (S%) of MDA-MB-361 cells co-
cultured for 48 h, with effectors, PBMC isolated from control 
healthy people and from breast carcinoma patients, in nutri-
ent medium with 10% of control, or autologous serum. E:T 
ratio was 5:1.
n=13  n=14
control
serum
n=20  n=14
autologous
serum
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cancer patients when control pooled serum was used (as
seen on Figure 2). Upon replacement of control serum
with autologous serum, the cytotoxic activity of patients'
PBMC was higher but not significantly (P = 0.09) than
that of controls PBMC (Figure 2). Similarly, patients'
PBMC activity was statistically enhanced (P < 0.003) by
the presence of autologous serum compared to their
action in pooled control serum (Figure 3). These data sug-
gest that autologous serum of patients with breast cancer
may contain a soluble facilitator of PBMC-mediated cyto-
toxicity, which is specific for each individual patient.
This anti-tumor humoral immunity present in autologous
serum, which contributed to the enhancement (≥  30%) of
PBMC cytotoxicity, was seen in 5/14 HER-2 positive
breast carcinoma patients, and in 4/13 healthy control
subjects Therefore it seems that this is not a breast cancer
patient specific phenomenon.
The addition of Herceptin to PBMC from controls and
from patients with breast cancer, significantly enhanced
suppression of target cell survival at the E:T ratio 5:1 (P <
0.02 and P < 0.004 respectively) (Figure 4). This means
that patients PBMC from breast cancer patients have not
loosed their ability to kill malignant cells through
Herceptin.
There were no statistically significant differences between
the percentage of CD16+ cells in patients and controls.
The clinical significance of the level of Herceptin depend-
ent cytotoxicity in some patients treated with Herceptin is
not available at the moment.
Discussion
Addition of targeted HER-2-specific passive immune ther-
apy for the treatment of patients with breast cancer may
complement conventional therapy [11]. However, some
patients do not successfully respond to such treatment. As
Herceptin is primarily an immunological agent the
potential of Herceptin to enhance anti-cancer immune
responses in vitro might guide the selection of patients for
Herceptin therapy. Our data suggest that MDA-MB-361
cells, over-expressing HER-2 are not significantly suscepti-
ble to direct Herceptin anti-proliferative action. This can
be due to the loss of tumor suppressor PTEN by MDA-MB-
361 cells which plays a central role in the transmission of
growth inhibitory signals induced by Herceptin [12].
The mean values of the survival (S%) of MDA-MB-361 cells  co-cultured for 48 h, with effectors PBMC, isolated from  control healthy people and from the breast carcinoma  patients, in nutrient medium with 10% of control, or autolo- gous serum Figure 3
The mean values of the survival (S%) of MDA-MB-361 cells 
co-cultured for 48 h, with effectors PBMC, isolated from 
control healthy people and from the breast carcinoma 
patients, in nutrient medium with 10% of control, or autolo-
gous serum. E:T ratio was 5:1 (*P < 0.003).
n=13  n=20
controls
PBMC
n=14  n=14
patients
PBMC
0
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40
60
80
100
120
S
%
control serum
autologous serum
*
Herceptin in the concentration of 21 µg/ml in the incubation  mixture of PBMC (from control healthy people and from  breast carcinoma patients) and target cells decreased MDA- MB-361 cell survival (S%), in medium with 10% of autologous  serum Figure 4
Herceptin in the concentration of 21 µg/ml in the incubation 
mixture of PBMC (from control healthy people and from 
breast carcinoma patients) and target cells decreased MDA-
MB-361 cell survival (S%), in medium with 10% of autologous 
serum. E:T ratio was 5:1 (*P < 0.02, **P < 0.004).
** *
0
20
40
60
80
100
120
S
%
-Herceptin
+Herceptin
n=20  n=20
controls
n=14  n=14
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In addition, it appears according to our observations that
PBMC from patients with breast cancer have non-signifi-
cantly lower cytotoxic potential against MDA-MB-361
cells compared to PBMC isolated from healthy donors.
However, patients PBMC in the presence of autologous
serum significantly (P < 0.003) enhanced their immune
reactivity possibly because of spontaneous humoral HER-
2 anti-tumor immunity. These findings are in accordance
with Disis et al. [13] reporting the existence of humoral
immunity in some patients with breast cancers.
Unexpectedly, the anti-tumor humoral immunity, which
Table 2: Survival of target tumor MDA/MB-361 cells incubated with breast cancer patients PBMC in nutrient medium with 10% pooled 
serum (Nc) or with 10% of autologous serum (Na) without or with 21 µg/ml Herceptin (Na+H). Effectors (E) to target tumor cells (T) 
ratio was 5:1.
Patient S N (%) S Na (%) S Na+H (%) CD16 (%)
1 7 33 02 13 2 . 0 2
2 4 23 91 31 8 . 9 8
3 7 36 93 01 6 . 6 8
4 4 92 72 42 5 . 7 6
5 8 72 31 2N D
6 6 96 24 9N D
7 55 33 5 28.00
8 53 11 8 25.32
9 4 94 01 15 . 4 7
10 51 57 33 4.84
11 24 34 13 ND
12 70 32 10 ND
13 40 35 19 11.81
14 74 14 9 25.59
ND – non-determined
Table 3: Survival of target tumor MDA/MB-361 cells incubated with healthy controls PBMC in nutrient medium with 10% pooled 
serum (Nc) or with 10% of autologous serum (Na) without or with 21 µg/ml Herceptin (Na+H). Effectors (E) to target tumor cells (T) 
ratio was 5:1.
Control S Nc (%) S Na (%) S Na+H (%) CD16 (%)
1 ND 103 49 15.00
2 N D 5 22 41 4 . 2 0
3 N D 7 35 51 0 . 0 0
4 N D 9 23 53 5 . 4 5
5 N D 6 61 7N D
6 N D 2 22 6N D
7 N D 8 95 8N D
8 105 85 85 ND
9 5 88 54 91 7 . 5 5
10 74 82 34 16.15
11 20 27 0 16.45
12 93 92 24 ND
13 34 0 0 8.98
14 40 26 26 12.48
15 40 30 21 9.49
16 29 25 26 4.62
17 46 25 22 9.49
18 53 8.8 7 32.19
19 74 29 13 13.2
20 47 16 10 34.58
ND – non-determinedPublish with BioMed Central    and   every 
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leads to decreased malignant cell survival was also found
in a minority of healthy people.
The significance of the existence of an effective anti-tumor
immunity in vitro in some patients with breast carcinoma
which is not effective in destroying tumors in vivo remains
unclear. Possibly, some proteins may inhibit the lytic
action of perforin and granzymes. One of such proteins
could be calreticulin that exerts several inhibitory actions
including the inhibition of C1q-dependent complement
activation [14]. This protein, together with perforin, is
present in the cytolytic granule of NK and cytotoxic T cells
protecting them from self destruction by perforin [15]. It
has been suggested that calreticulin stabilizes membranes
and indirectly prevents polyperforin pore formation,
therefore, inhibiting target cell susceptibility to effector
cell killing [16,17]. The over-expression of serpins by
some tumor cells could also inhibit granzim A or
granzyme B lytic activity too [18,19]. Results obtained in
this work point to the new experiments aiming to deter-
mine the utility of in vitro immunological tests for the pre-
diction of patients response to immunotherapy; i.e. the
relevance of different levels of calreticulin and/or serpins
in target cells used in vitro and in cells from malignant
tumor specimens in immunological tumor escape needs
to be determined.
Absence of statistically significant difference between per-
centage of CD16+ cells in patients and in controls suggest
that ADCC mediated by NK cells is likely preserved in
patients with breast carcinoma.
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